InsiderSignal.AI

InsiderSignal.ai

EDSA - Edesa Biotech, Inc.

Insider Purchase by Nijhawan Pardeep (CEO, 10%)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Nijhawan Pardeep, serving as CEO, 10% owner at Edesa Biotech, Inc. (EDSA), purchased 10,000 shares at $4.26 per share, for a total transaction value of $42,560.00. Following this transaction, Nijhawan Pardeep now holds 1,138,241 shares of EDSA.

This purchase represents a 1.00% increase in Nijhawan Pardeep's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, March 4, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 5, 2026, 1 day after the trade was made.

Edesa Biotech, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Nijhawan Pardeep

CEO, 10%

Pardeep Nijhawan, MD, FRCPC, AGAF, age 54, is the Chief Executive Officer, Corporate Secretary, and a director of Edesa Biotech, Inc. (EDSA) since June 7, 2019. He founded Edesa Biotech Research in January 2015, which became a key part of the company's pipeline development, and has over 20 years of experience in life sciences leadership spanning finance, marketing, strategy, and business development.[[1]](https://fintool.com/app/research/companies/EDSA/people/pardeep-nijhawan)[[2]](https://www.marketscreener.com/insider/PARDEEP-NIJHAWAN-A2A6CJ/)[[5]](https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/vwRg?cno=367429&regId=916760) Nijhawan holds an MD from the University of Ottawa, completed an internship at Yale, and finished an internal medicine residency and fellowship at the Mayo Clinic. His career highlights include founding and successfully exiting Medical Futures Inc. (sold to Tribute Pharmaceuticals in 2015), Exzell Pharma (sold to BioLab Pharma in 2022), and Digestive Health Clinic, where he continues as a board member. He recently demonstrated confidence in Edesa Biotech through personal investments, including direct and indirect purchases of company shares in early 2026 (e.g., 10,000 shares on March 3 at $3.63 via his professional corporation, 3,000 shares on March 2) and 100 Series B-1 Preferred shares for $1.0M on February 12, 2025, holding approximately 19.99% ownership.[[1]](https://fintool.com/app/research/companies/EDSA/people/pardeep-nijhawan)[[3]](https://www.stocktitan.net/sec-filings/EDSA/form-4-edesa-biotech-inc-insider-trading-activity-bd09613a5ac1.html)[[4]](https://www.stocktitan.net/sec-filings/EDSA/form-4-edesa-biotech-inc-insider-trading-activity-e8c10b0b8266.html)[[7]](https://whalewisdom.com/filing/nijhawan-pardeep-4-2026-03-02-170559-0500-edsa)

View full insider profile →

Trade Price

$4.26

Quantity

10,000

Total Value

$42,560.00

Shares Owned

1,138,241

Trade Date

Wednesday, March 4, 2026

2 days ago

SEC Filing Date

Thursday, March 5, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Edesa Biotech, Inc.

Company Overview

No company information available
View news mentioning EDSA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4525052

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime